Clinical Data Lilly’s new obesity pill passes heart safety test in diabetes BioPharma DiveThe findings, which come amid FDA scrutiny of Foundayo s safety, will enable Lilly to seek a new clearance in diabetes.Clinical DataMetabolic & GLP-1Read full story pharminent April 16, 2026 (Last updated: April 16, 2026) BioPharma Dive The findings, which come amid FDA scrutiny of Foundayo s safety, will enable Lilly to seek a new clearance in diabetes. Clinical DataMetabolic & GLP-1Read full story Post navigation Previous: Lilly debuts more Foundayo data as FDA requests post-marketing trialsNext: FDA moves toward easing restrictions on certain peptides Related Stories Clinical Data BridgeBio stands up to Pfizer in ATTR-CM as late-stage data hint at better survival pharminent May 12, 2026 Clinical Data Novo says high-dose Wegovy can cause 28% weight loss pharminent May 12, 2026 Clinical Data Pulsesight reports positive phase 1 data for PST611 in dry AMD pharminent May 11, 2026
